Ch. 181SMA Drug Price Announced, National Rare Disease Patient Alliance
Sanqing announced that its SMA gene drug would cost 300,000 yuan domestically, with insurance reducing patients’ payments to a little over 100,000 yuan, and the news reshaped the rare-disease drug market. As Longtu’s downloads surged, Xiang Gaofei planned to expand its reach beyond rare-disease patients.
- Sanqing set the SMA gene drug’s price at 300,000 yuan and secured medical insurance coverage, prompting families and online commenters to praise its affordability and charitable drug donations.
- Western patients and netizens reacted to the drug’s 300,000-dollar overseas price, and some SMA families traveled to China for treatment.
- Novartis, Biogen, and Roche shares hit their limit down, and the companies announced further price cuts as Sanqing became a major rare-disease gene-therapy force.
- Doctors and patient groups recommended Longtu to rare-disease patients, helping the app reach fifteen million downloads.
- Xiang Gaofei celebrated Longtu’s growth with Wang Dong, then said they should intensify promotion because the app could serve all sick people and eventually everyone.